The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.
The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback